Alexei Navalny: Doctors say Putin critic can't be moved to Germany
21-08-2020, 18:57

Font size: [ A+ ] / [ A- ]

Russian doctors say leading opposition figure Alexei Navalny - who supporters believe was poisoned - remains too ill to be moved to Germany for treatment.

Mr Navalny has been in a coma since Thursday when he fell ill on a flight. His supporters called the doctors' decision "a direct threat to his life".

The doctors say no poison was found in his body.

The prominent critic of President Vladimir Putin has consistently exposed official corruption in Russia.

He has served multiple jail terms.

His team suspects a poisonous substance was put in his tea at an airport cafe in the city of Tomsk as he prepared to fly to Moscow.

German doctors have now been given access to him in hospital, one of his aides told reporters.

At a news conference in Berlin, Leonid Volkov said a medically equipped plane sent from Germany was still waiting for him in the Siberian city of Omsk, where he is in hospital.

In a preliminary diagnosis on Friday, doctors said his condition might be the result of a "metabolic disorder" caused by low blood sugar.

The head doctor at the hospital treating Mr Navalny in Omsk in Siberia said the patient was too unstable to be transferred and that legal questions would need to be resolved before any move.

Mr Navalny's team said it was "deadly" for him to remain in the hospital.

"The ban on the transportation of Navalny is an attempt on his life," his spokeswoman Kira Yarmysh wrote on Twitter.

What's happening with efforts to move him?

The Berlin-based Cinema for Peace Foundation organised an air ambulance to pick up Mr Navalny and bring him back to Berlin, where it said the Charite hospital was ready to treat him.

It said the aircraft had medical equipment and a team specialised in treating coma patients on board.

The Cinema for Peace Foundation was founded by activist and filmmaker Jaka Bizilj. In 2018, it arranged for the treatment of Pyotr Verzilov - an activist with Russian protest group Pussy Riot - who had symptoms of poisoning.

The air ambulance for Mr Navalny arrived in Omsk on Friday morning.

Mr Navalny's wife Yulia has written to President Putin asking him to allow her husband to be moved.

Mr Putin's spokesman Dmitry Peskov said on Thursday that the Kremlin would help move Mr Navalny abroad if necessary and wished him a "speedy recovery". On Friday, he said transporting him by air "may pose a threat to his health".

The hospital said it would not hand Mr Navalny over. Yulia Navalnaya told reporters she believed the doctors were seeking to cover up her husband's poisoning.

"We certainly believe that it is done to make sure that a chemical substance which is in Alexei's body will dissolve," she said. "We certainly cannot trust this hospital".

Timeline: Navalny targeted

April 2017: He was taken to hospital after an antiseptic green dye was splashed on his face in Moscow. It was the second time he was targeted with zelyonka ("brilliant green" in English) that year. "It looks funny but it hurts like hell," he tweeted following the attack.

July 2019: He was sentenced to 30 days in prison after calling for unauthorised protests. He fell ill in jail and doctors said he had suffered an acute allergic reaction, diagnosing him with "contact dermatitis". His own doctor suggested he might have been exposed to "some toxic agent" and Mr Navalny said he thought he might have been poisoned.

December 2019: Russian security forces raided the offices of his Anti-Corruption Foundation, taking laptops and other equipment. CCTV footage showed officials using power tools to get through the door. Earlier that year, his organisation was declared a "foreign agent".

The German government said it was in touch with officials in Moscow to find a solution to the "humanitarian emergency".

The EU called for Mr Navalny to be "safely and speedily transferred abroad" and urged a "swift, independent, transparent investigation" into the suspected poisoning.

The US Embassy in Russia said that, "if true", the suspected poisoning of Mr Navalny "represents a grave moment for Russia".

How did he end up in hospital?

Mr Navalny fell ill during a flight from Tomsk to Moscow and his plane made an emergency landing in Omsk.

"Alexei has toxic poisoning," Ms Yarmysh tweeted.

Video footage on social media showed Mr Navalny being taken on a stretcher to an ambulance on the airport runway.

Other disturbing video appeared to show a stricken Mr Navalny in pain on the flight. Passenger Pavel Lebedev said he heard the activist "screaming in pain".

Another photograph on social media purported to show Mr Navalny drinking from a cup at a Tomsk airport cafe.

What's the latest on his condition?

Alexander Murakhovsky, the head doctor at the Siberian hospital, said a preliminary diagnosis of a "metabolic disorder" had been given.

"This could have been caused by a sharp fall in blood sugar levels, which caused a loss of consciousness," he said.

The hospital says its tests have found no traces of poison in Mr Navalny's blood so far. Mr Murakhovsky said traces of a common industrial chemical used in plastic cups had been found on Mr Navalny's clothes and fingers.

He earlier said there were five possible diagnoses.

Deputy head doctor Anatoly Kalinichenko said "poisoning as a diagnosis remains on the back burner" but that doctors did not believe poisoning was responsible.

Ivan Zhdanov, an associate of Mr Navalny, said on Friday he had been told by a transport police official that a "deadly" substance had been used, which posed a threat not only to the opposition figure's life, but also those around him, meaning that protective suits should be worn.

State news agency Tass cited a police officer saying: "We can't rule out that he drank or took something himself". Ms Yarmysh dismissed this as "complete rubbish".

 

BBC

 

Comments: 1
#1   Zella
      
The long‑term use of ipamorelin, particularly in the form known as CJC Ipamorelin, has raised
questions among users and healthcare professionals alike about potential side
effects that may arise over months or years of therapy. While short‑term trials have generally reported a favorable safety profile, extended exposure can lead
to subtle physiological changes that warrant careful monitoring.
Understanding these risks is essential for anyone considering chronic
use, whether for bodybuilding, anti‑aging, or medical purposes such as growth hormone deficiency treatment.




CJC Ipamorelin Side Effects: What You Need to Know

The most commonly cited short‑term side effects of ipamorelin include mild injection site
reactions, transient headaches, and occasional nausea.
However, when used over a longer period, additional concerns have emerged.

One of the primary issues is the potential for elevated growth hormone
levels to affect insulin sensitivity. Chronic exposure may lead to
changes in glucose metabolism that could predispose individuals to insulin resistance or
type 2 diabetes. Another area of concern involves the endocrine system’s feedback
loops; sustained stimulation of growth hormone release can alter the regulation of other pituitary hormones
such as prolactin and thyroid‑stimulating hormone, potentially
causing imbalances.



Patients who have reported long‑term effects also mention increased water retention, which may manifest as mild edema in the extremities or face.
This fluid shift is believed to be linked to growth hormone’s influence
on vasopressin secretion and renal handling of sodium.
In addition, some users describe an enhanced tendency
toward fatigue or a feeling of heaviness during
prolonged activity, possibly due to altered energy metabolism.




Another subtle but noteworthy long‑term effect involves the cardiovascular system.
Growth hormone has trophic effects on cardiac tissue, and prolonged high
levels could contribute to changes in heart structure or function over time.

While definitive clinical evidence is still limited, animal studies suggest that chronic growth hormone excess can lead to myocardial
hypertrophy, which may increase the risk of arrhythmias or reduced cardiac efficiency.




What is CJC Ipamorelin?

CJC Ipamorelin is a synthetic peptide belonging to the
ghrelin‑like class of growth hormone secretagogues.
It was first developed by researchers at the University of Kansas and later refined by pharmaceutical companies seeking
a selective, potent stimulator of growth hormone release.
The peptide’s design allows it to bind with high affinity
to the growth hormone secretagogue receptor while sparing other receptors that could
trigger unwanted cjc-1295/ipamorelin side
effects
effects such as increased cortisol or prolactin.



Unlike some older secretagogues, CJC Ipamorelin has a minimal impact
on appetite and does not typically stimulate significant food intake.
This feature makes it attractive for users who want to increase lean muscle mass without gaining excess body fat.
In clinical settings, it is sometimes prescribed for growth hormone deficiency or
as part of anti‑aging protocols aimed at improving tissue repair and metabolic health.




The peptide’s pharmacokinetics are relatively straightforward; after subcutaneous
injection it reaches peak plasma concentration within 30
minutes and has a half‑life of roughly one
hour. Because of its short duration, users often administer multiple doses per day
to maintain steady growth hormone levels. The
safety profile in acute studies is reassuring, but the long‑term picture remains less clear.




Feeling Light‑headed or Weak

One of the more frequently reported subjective experiences among long‑term ipamorelin users is a sensation of lightness or weakness that
occurs intermittently, especially after dosing. This feeling can range from mild dizziness to a pronounced sense of fatigue.
The underlying mechanism is not fully understood but may involve
transient changes in blood pressure or neurohumoral regulation.



Growth hormone has vasoactive properties; it can dilate blood vessels and
alter peripheral resistance. In the context of repeated peptide administration, these vascular effects could
cause brief episodes of lowered blood pressure, which would
manifest as light‑headedness. Additionally, ipamorelin’s action on the hypothalamic‑pituitary
axis may influence catecholamine levels, further contributing to fluctuations
in energy and alertness.



Another potential contributor is the redistribution of fluid within the body.
As growth hormone promotes sodium retention and increases plasma volume, some individuals experience a feeling
of heaviness or sluggishness when their circulatory system is adjusting to these changes.
Over time, this may manifest as intermittent weakness, especially during periods
of intense training or prolonged standing.



Monitoring for light‑headedness or weakness should involve keeping a log of symptoms relative to dosing times and activity
levels. If the episodes become frequent or severe, it may be
advisable to adjust the dosage schedule, reduce frequency, or consult a medical professional for evaluation of blood pressure and endocrine function.
6 October 2025 02:18
Add Comments

Name:*
E-Mail:
  Geo Keyboard  
 

Dear reader, guardian.ge welcomes your comments. Please express your views on topic and be respectful of others.

bold italic underline strike | align left centered align right | Ensert smilies insert linkInsert protected URL Choice the color | hidden text insert quote Convert selected text from transliteration to Cyrillic alphabet Insert spoiler

Code: *